


## NCCN Guidelines® for Adult and AYA\* Patients with ALL<sup>1</sup>



### Diagnostic workup

Baseline flow cytometric and/or molecular characterization of leukemic clone to facilitate subsequent MRD analysis

### Minimal residual disease (MRD) assessment:

- Additional MRD assessment time points should be guided by the regimen used
- Serial monitoring frequency may be increased in patients with molecular relapse or persistent low-level disease burden
- Consider periodic MRD monitoring ( $\geq$  every 3 months) for patients with complete molecular remission (undetectable levels). Increased frequency may be indicated for detectable levels

\*The ALL Panel considers AYA to be within the age range of 15-39 years. However, this age is not a firm reference point because some of the recommended regimens have not been comprehensively tested across all ages.

#### Reference:

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed July 29, 2021. To view the most recent and complete version of the guideline, go to [NCCN.org](https://www.nccn.org). NCCN makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way.

clonoSEQ® is available as an FDA-cleared *in vitro* diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit [clonoSEQ.com/technical-summary](https://clonoSEQ.com/technical-summary).